Pipeline Overview

Category	Product Candidate	Indication	Discovery	Preclinical	Phase 1	Phase 2	Phase 3	Market
Virology: Liver
	HCV	Protease Inhibitor	Glecaprevir*
	HBV	Core Inhibitor	EDP-514**
Virology: Respiratory
	RSV	N-Protein Inhibitor	Zelicapavir (EDP-938) RSVPEDs
			RSV	N-Protein Inhibitor	Zelicapavir (EDP-938) RSVHR
		RSV	L-Protein Inhibitor	EDP-323 (challenge study)
	COVID-19	3CL Protease Inhibitor	EDP-235** SPRINT
Immunology
	CSU	KIT Inhibitor
	Various	Undisclosed

Virology: Liver
HCV Protease Inhibitor
Discovery	Preclin	Phase 1	Phase 2	Phase 3	Market
Glecaprevir*
HBV Core Inhibitor
Discovery	Preclin	Phase 1	Phase 2	Phase 3	Market
EDP-514**

Virology: Respiratory
RSV N-Protein Inhibitor
Discovery	Preclin	Phase 1	Phase 2	Phase 3	Market
Zelicapavir (EDP-938) RSVPEDs
RSV N-Protein Inhibitor
Discovery	Preclin	Phase 1	Phase 2	Phase 3	Market
Zelicapavir (EDP-938) RSVHR
RSV L-Protein Inhibitor
Discovery	Preclin	Phase 1	Phase 2	Phase 3	Market
EDP-323 (challenge study)
COVID-19 3CL Protease Inhibitor
Discovery	Preclin	Phase 1	Phase 2	Phase 3	Market
EDP-235** SPRINT

Immunology
CSU KIT Inhibitor
Discovery	Preclin	Phase 1	Phase 2	Phase 3	Market
Various Undisclosed
Discovery	Preclin	Phase 1	Phase 2	Phase 3	Market

*Fixed-dose antiviral combination contains glecaprevir and AbbVie's NS5A inhibitor, pibrentasvir. Marketed by AbbVie as MAVYRET® (U.S.) and MAVIRET® (ex-U.S.).
**Continued development dependent on a future collaboration.